EurekAlert! COVID-19 Online Newsroom - Latest News Releases

Latest News Releases

Updates every hour. Last Updated: 24-Jun-2026 01:15 ET (24-Jun-2026 05:15 GMT/UTC)

Interim estimated effectiveness of 2025-2026 COVID-19 vaccines in adults using a test-negative design

JAMA Network
Peer-Reviewed Publication

About The Study: In this study, receipt of 2025-2026 COVID-19 vaccination was associated with additional protection beyond existing immunity in adults against medically attended COVID-19, including emergency department/urgent care encounters and hospitalizations, compared with no receipt of a 2025-2026 vaccine dose. These findings suggest that adults can reduce their likelihood of severe COVID-19–associated outcomes by obtaining a 2025-2026 COVID-19 vaccination.

Journal: JAMA Network Open

Job dissatisfaction, education drive nurse turnover

New York University
Peer-Reviewed Publication

Job dissatisfaction and pursuing additional degrees were the leading reasons that nurses left their roles a few years into the pandemic, according to a new study published in the journal Health Affairs Scholar.

The findings point to actionable strategies that employers can use—such as flexible or non-traditional scheduling—to improve job satisfaction, work-life balance, and curb costly turnover.

Journal: Health Affairs Scholar

Single amino acid change may help viruses jump from bat to human

University of California - San Francisco
Peer-Reviewed Publication

Most pandemics start when a pathogen spreads from animals to humans. It’s a leading explanation for the COVID-19 pandemic: the SARS-CoV-2 virus, which causes COVID-19, is a cousin to coronaviruses that live in bats.

Journal: Cell Host & Microbe
Funder: Howard Hughes Medical Institute, James B. Pendleton Charitable Trust, Roddenberry Foundation, P. and E. Taft, Gladstone Institutes, Fast Grants, Innovative Genomics Institute, Chan Zuckerberg Biohub – San Francisco, ANR EmerCoV

2024-2025 COVID-19 vaccine and major adverse cardiovascular events among US veterans

JAMA Network
Peer-Reviewed Publication

In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19–associated major adverse cardiovascular event (MACE), with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19–associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine’s protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae.

Journal: JAMA Internal Medicine

Estimated effectiveness of 2024-2025 COVID-19 vaccines in adults

JAMA Network
Peer-Reviewed Publication

In this test-negative case-control study, 2024-2025 COVID-19 vaccination was associated with reduced likelihood of medically attended COVID-19–associated outcomes among immunocompetent and immunocompromised adults, highlighting the importance of adults receiving recommended COVID-19 vaccinations.

Journal: JAMA Internal Medicine

COVID-19 vaccine effectiveness among older adults

JAMA Network
Peer-Reviewed Publication

Vaccines administered in autumn and winter 2025 to 2026 showed approximately 55% effectiveness against symptomatic disease among older adults within 2 months of vaccination. The low uptake of vaccines, which showed substantial short-term effectiveness, suggests missed opportunities for preventing symptomatic COVID-19 among unvaccinated vulnerable groups.

Journal: JAMA Network Open

Study of 5.8 billion medicines dispensed in England exposes stark health inequalities

Health Data Research UK
Peer-Reviewed Publication

Scientists have revealed striking inequalities and changing trends in medicines dispensing for more than 52 million people living in England during and after the COVID-19 pandemic.

Journal: Nature Health
Funder: National Institute for Health Research, British Heart Foundation

Pandemic in fast forward

Weizmann Institute of Science
Peer-Reviewed Publication

Researchers have now recreated in a test tube, within just a few months, the evolutionary path the coronavirus followed during the COVID-19 pandemic – from the original Wuhan strain to the emergence of the highly contagious Omicron variants.

Journal: Nature Communications

Antibody clues could improve long COVID care and prognosis

Okayama University
Peer-Reviewed Publication

Long COVID (LC), characterized by onset of symptoms within 3 months of COVID-19, poses a major clinical challenge. This highlights the need for biomarkers to evaluate the pathophysiology of LC. In this context, researchers have analyzed the antibody titers against SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in patients with LC. It was observed that N-antibody levels reflected prior infection severity, while lower S-antibody levels were linked to memory problems and poor quality of life.

Journal: British Journal of Biomedical Science
Funder: AMED, Japanese Society of Hospital General Medicine, Ofuji Endocrine Medical Award, Growth Science Foundation, Kobayashi Magobe Memorial Medical Foundation

Nursing job turnover has nearly doubled since pandemic

University of Michigan
Peer-Reviewed Publication

The COVID-19 pandemic did not push nurses out of hospitals or other care settings as feared, but nurses left their primary jobs at nearly double the rate from 2018 to 2022, a new University of Michigan study found.

Journal: Medical Care

New study shows metformin given during acute COVID-19 infection reduced risk of clinician-diagnosed long COVID by 50%

University of Minnesota Medical School
Peer-Reviewed Publication

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

Journal: Clinical Infectious Diseases

Skipping meals to selling assets: COVID-19 and coping strategies of vulnerable Indian households

Lancaster University
Peer-Reviewed Publication

The study documents how vulnerable families in India coped with food insecurity during the pandemic. It highlights how interviewed families sometimes went without food, medicine, and other essentials to cope with the fallout of the pandemic.

Journal: PLOS One

Health-related quality of life in Japan steadily declined from 2017 to 2024

Hiroshima University
Peer-Reviewed Publication

A nationwide study tracking Japanese adults before, during, and after the COVID-19 pandemic found that health-related quality of life steadily declined over seven years and did not rebound after the public health emergency ended. Researchers say the decline may reflect the cumulative impact of pandemic-related changes in physical activity, mental well-being, and social interaction among working-age adults across Japan.

Journal: Scientific Reports
Funder: Japan Ministry of Health, Labour and Welfare

The DIVINE cohort makes data from more than 5,800 patients hospitalised with COVID-19 available to the scientific community

Germans Trias i Pujol Research Institute
Peer-Reviewed Publication

The DIVINE cohort brings together clinical data from 5,813 patients hospitalised with COVID-19 during the first four waves of the pandemic and makes it available to the scientific community through an open, accessible and reusable resource. Published in Scientific Data, this multicentre database has already contributed to several studies and aims to support further research into the clinical progression of COVID-19, associated risk factors and the development of predictive models.

Journal: Scientific Data

New ‘universal vaccine’ technology could protect us from future virus outbreaks

University of Cambridge
Peer-Reviewed Publication

- A Cambridge-led team has developed a way to engineer better vaccines that could provide broad protection from thousands of variants of viruses - such as coronaviruses or Ebola - in a single vaccine.

- This represents a fundamental new vaccine technology that could prevent future pandemics before they begin.

- The team used the technology to engineer a vaccine designed to protect against a wide range of coronaviruses, including the cause of the COVID pandemic.

- The results of the first-in-human clinical trial of this technology found it is safe and well tolerated.

Journal: Journal of Infection
Funder: Innovate UK

1
2
3